Anti‑Factor Xa–guided enoxaparin dosing for preventing blood clots in adults with major burns
Official title: Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management
Run by Ain Shams University · NCT07464808 · Data updated 2026-11-12
This trial will test whether using anti‑Factor Xa blood levels to guide enoxaparin dosing prevents venous blood clots better than standard weight‑based dosing in adults with moderate-to-large thermal burns.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo, Abbassia) |
| Status | Recruiting |
| Started | November 28, 2025 |
| Main results expected | January 30, 2027 |
| Study ends | November 30, 2027 |
| Registry record updated | March 11, 2026 |
| Trial ID | NCT07464808 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 21 or older with thermal burns of 20–60% TBSA admitted to the burn ICU within 48 hours who require VTE prophylaxis and can provide consent are ideal candidates.
✕Probably not a fit
Patients with pre-existing coagulopathy or on prior anticoagulation, those with severe comorbidities (like end‑stage renal failure or advanced liver disease), those needing therapeutic anticoagulation, and patients with very low or very high body weight (e.g., <45 kg or ≥150 kg) are unlikely to be eligible or benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with thermal burns covering 20–60% total body surface area who are admitted within 48 hours and need VTE prophylaxis are randomized 1:1 to weight‑based enoxaparin (1 mg/kg twice daily, max 150 mg) or anti‑Xa‑guided dosing. In the anti‑Xa arm a peak level is measured 4 hours after the third dose with a prophylactic target of 0.2–0.4 IU/mL and dose adjustments of ±10 mg are made until the target is reached. The weight‑based arm receives standard dosing without routine anti‑Xa monitoring. Prophylaxis continues until mobilization or hospital discharge and patients are followed for venous thromboembolic events.
Why it matters
Potential benefit: If successful, tailoring enoxaparin by anti‑Factor Xa levels could lower the risk of VTE and optimize dosing safety for burn patients.
How similar studies have gone: Anti‑Xa‑guided dosing has produced mixed results in other surgical and trauma populations and remains relatively untested specifically in burn patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults (≥21 years) admitted to the burn unit with thermal burns ≥20% TBSA and \< 60%. 2. Admission to BICU within 48 hours of burn injury. 3. Indication for VTE prophylaxis (e.g., immobilized, surgical intervention). 4. Ability to provide informed consent Exclusion Criteria: 1. Pre-existing coagulopathy or anticoagulant therapy prior to injury. 2. Patients with severe comorbidities (e.g., end-stage renal failure, advanced malignancy, hepatic disease). 3. Need for therapeutic anticoagulant therapy. 4. patients with extremes of weight, (45kg \>=weight \>= 150kg).
Where it's running
-
Ain Shams University
Cairo, Abbassia, Egypt Recruiting
Study contacts
- Study coordinator: Doaa Ahmed Diaa El din Ibrahim, MD
- Email: Doaaeldin@med.asu.edu.eg
- Phone: 01128904628
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Safety of perioperative blood thinner management in people with cancer undergoing surgery or procedures
This study tests how safe current practices are for stopping or continuing blood thinners in adults with cancer who are having surgery or procedures, to see if bleeding or clots are affected.
-
Reduced‑dose apixaban or rivaroxaban versus daily low‑molecular‑weight heparin for people with blood cancers
This trial will test whether reduced‑dose apixaban or rivaroxaban pills can prevent blood clots as well and as safely as daily low‑molecular‑weight heparin injections in people with hematologic malignancies.
-
Monitoring adults after venous thromboembolism
This project tests whether using bleeding-and-recurrence risk scores together with multidisciplinary thrombosis meetings helps guide anticoagulant treatment for adults hospitalized with venous thromboembolism.
-
Examining blood clotting in pregnant women and the effects of low molecular weight heparin
This study looks at how blood clotting changes during and after pregnancy to see if a blood thinner called low molecular weight heparin works better for pregnant women at risk of blood clots.
-
Comparing antithrombotic therapies for patients with acute venous thromboembolism and a history of cardiovascular disease
This study is testing if combining blood thinners with another type of medication can help people with blood clots and a history of heart disease stay safe and healthy.
-
Prolonged anticoagulation for preventing blood clots in autoimmune hemolytic anemia
This study is testing if longer use of blood thinners can help prevent blood clots in people with autoimmune hemolytic anemia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.